Holen Sie sich die Stockscreener-App
26.44
1.07%
0.28
Handel nachbörslich:
26.89
0.45
+1.70%
Schlusskurs vom Vortag:
$26.16
Offen:
$26.23
24-Stunden-Volumen:
2.08M
Relative Volume:
0.72
Marktkapitalisierung:
$4.22B
Einnahmen:
$295.41M
Nettoeinkommen (Verlust:
$-49.64M
KGV:
-80.76
EPS:
-0.3274
Netto-Cashflow:
$-29.54M
1W Leistung:
+3.93%
1M Leistung:
+17.30%
6M Leistung:
+65.04%
1J Leistung:
+103.86%
1-Tages-Spanne:
$26.11
$26.87
1-Wochen-Bereich:
$24.93
$26.87
52-Wochen-Spanne:
$12.00
$26.87
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Firmenname
Adaptive Biotechnologies Corp
Sektor
Branche
Telefon
206-659-0067
Adresse
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
26.44 | 4.06B | 295.41M | -49.64M | -29.54M | -0.3274 |
TMO
Thermo Fisher Scientific Inc
|
630.70 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.68 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
338.70 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
157.69 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
262.38 | 42.15B | 16.63B | 1.39B | 2.12B | 8.0674 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-09-30 | Eingeleitet | Guggenheim | Buy |
| 2025-06-18 | Eingeleitet | Craig Hallum | Buy |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-12-21 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Underperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Bestätigt | BTIG Research | Buy |
| 2022-02-16 | Bestätigt | BofA Securities | Buy |
| 2022-02-16 | Bestätigt | Goldman | Neutral |
| 2022-02-16 | Bestätigt | JP Morgan | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-03-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Eingeleitet | Goldman | Buy |
| 2019-07-23 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-22 | Eingeleitet | Cowen | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Neutral |
| 2019-07-22 | Eingeleitet | Guggenheim | Buy |
| 2019-07-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
Adaptive Biotechnologies Stock Has Doubled in the Past Year. Here’s What Could Come Next. - inkl
Bank of America Corp DE Acquires 421,645 Shares of Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies director Robert Hershberg sells $748k in shares - Investing.com
Adaptive Biotechnologies director Robert Hershberg sells $748k in shares By Investing.com - Investing.com South Africa
Adaptive Biotechnologies (NASDAQ:ADPT) Director Robert Hershberg Sells 30,664 Shares of Stock - MarketBeat
Adaptive Biotechnologies Director Robert Hershberg Executes Stock Option and Sells Shares - Kalkine Media
Adaptive Biotech (NASDAQ: ADPT) ex-officer to sell 402,160 shares - Stock Titan
Adaptive Biotechnologies (NASDAQ: ADPT) director exercises option at $6.32 strike - Stock Titan
Adaptive Biotechnologies director Neupert sells $3.1m in stock By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies CEO Chad Robins sells $14.88m in shares By Investing.com - Investing.com India
Adaptive Biotechnologies director Neupert sells $3.1m in stock - Investing.com
Adaptive Biotechnologies CEO Chad Robins sells $14.88m in shares - Investing.com
Adaptive Biotechnologies (NASDAQ:ADPT) CEO Chad Robins Sells 278,676 Shares - MarketBeat
Adaptive Biotechnologies (ADPT) CEO sells 600K shares after exercising options - Stock Titan
Adaptive Biotechnologies (ADPT) director sells stock after option exercise - Stock Titan
Adaptive Biotechnologies (NASDAQ: ADPT) ex-officer plans new share sale - Stock Titan
Adaptive Biotechnologies stock hits 52-week high at 26.16 USD By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies (NASDAQ:ADPT) Sets New 1-Year HighHere's What Happened - MarketBeat
Adaptive Biotechnologies stock hits 52-week high at 26.16 USD - Investing.com
66,000 Shares in Adaptive Biotechnologies Corporation $ADPT Bought by Handelsbanken Fonder AB - MarketBeat
Adaptive Biotechnologies (NASDAQ: ADPT) director plans to resell 30,664 shares - Stock Titan
Adaptive Biotechnologies (NASDAQ: ADPT) insider plans more sales after $7.96M already sold - Stock Titan
Adaptive Biotechnologies (ADPT) ex-officer plans cashless option share sale - Stock Titan
Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science - GeekWire
Adaptive Biotechnologies (NASDAQ: ADPT) insider plans multimillion stock sale - Stock Titan
Adaptive Biotechnologies (ADPT) plans multi-million-dollar stock sale for 2026 - Stock Titan
Adaptive Biotechnologies (NASDAQ: ADPT) lines up six-figure share sale for 2026 - Stock Titan
Dimensional Fund Advisors LP Cuts Stock Holdings in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
576,266 Shares in Adaptive Biotechnologies Corporation $ADPT Bought by Wasatch Advisors LP - MarketBeat
Adaptive Biotechnologies (ADPT) Stock Looks Fair On Cash Flow Yet Rich On Sales - simplywall.st
Adaptive Biotechnologies CCO Susan Bobulsky sells $75,000 in shares By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies CCO Susan Bobulsky sells $75,000 in shares - Investing.com
Adaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 3,000 Shares of Stock - MarketBeat
Adaptive Biotechnologies (ADPT) CCO Bobulsky sells 3,000 shares under plan - Stock Titan
Adaptive Biotechnologies Corp (ADPT) Stock Analysis: Navigating the Growth Path with a 21.5% Revenue Surge - DirectorsTalk Interviews
Adaptive Biotechnologies (NASDAQ:ADPT) Sets New 12-Month HighHere's Why - MarketBeat
ADPT (ADPT) insider outlines Form 144 sale of 3,000 shares - stocktitan.net
Adaptive Biotechnologies stock hits 52-week high at 25.04 USD By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies stock hits 52-week high at 25.04 USD - Investing.com
Renaissance Technologies LLC Acquires Shares of 239,800 Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies Corp (ADPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Adaptive Biotechnologies Corp (ADPT) Stock News Today - TradingKey
Adaptive Biotechnologies Corp (1HM) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Adaptive Biotechnologies Corp (1HM) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Adaptive Biotechnologies Corp (1HM) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Adaptive Biotechnologies Corp (1HM) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Adaptive Biotechnologies Corp (1HM) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Adaptive Biotechnologies Corp (1HM) Q4 2024 Earnings ReportResults, Call & Slides - tipranks.com
Adaptive Biotechnologies Corp (1HM) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Adaptive Biotechnologies Corp (ADPT) Shares Fall 4.1% -- GF Value Says Still Overvalued - GuruFocus
Adaptive Biotechnologies Corp Q2 2026: Revenue $71.6M, EPS $(0.25) — 10-Q Summary - TradingView
Finanzdaten der Adaptive Biotechnologies Corp-Aktie (ADPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):